Abaloparatide

Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP), sharing 76% sequence homology with PTHrP(1-34) and 41% homology with parathyroid hormone (PTH)(1-34). Its molecular formula is C174H299N56O49 (molecular weight approximately 3960 Da). The compound was originally developed at Ipsen under the designation BIM-44058/BA058.

The defining pharmacological feature of abaloparatide is its selective binding to the RG (G-protein-coupled, or "active") conformation of the parathyroid hormone type 1 receptor (PTH1R), the primary receptor expressed on osteoblasts and osteocytes. Studies using competitive binding assays demonstrate that abaloparatide binds the RG conformation with an IC50 of approximately 0.20 nM, while its affinity for the R0 (G-protein-independent) conformation is approximately 316 nM — a selectivity ratio of roughly 1,600-fold. By contrast, PTH(1-34) (teriparatide) exhibits only a 12-fold RG:R0 differential, meaning teriparatide occupies the R0 state far more persistently.

This conformational bias has functional consequences downstream. RG-selective engagement produces transient cyclic AMP (cAMP) signaling: after ligand washout, residual cAMP from abaloparatide-treated cells is approximately 2-fold lower than that from teriparatide-treated cells over a 150-minute window. Transient, intermittent PTH1R activation favors net bone formation because it promotes osteoblast proliferation and inhibits osteoblast apoptosis without sustaining the prolonged resorptive signaling associated with continuous receptor occupancy.

• The cAMP signal activates protein kinase A (PKA), which drives osteoblast differentiation and bone matrix synthesis. • Osteoclast coupling to the remodeling cycle is comparatively muted, resulting in a lower rate of hypercalcemia than observed with teriparatide. • The ERK-1/2 pathway is activated with potency equivalent to other PTH1R ligands, contributing to osteoblast survival.

The pivotal Phase 3 Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE; NCT01343004) enrolled 2,463 postmenopausal women aged 49 to 86 years with osteoporosis, randomized to subcutaneous abaloparatide 80 mcg once daily, open-label teriparatide 20 mcg once daily, or placebo for 18 months (March 2011 to October 2014). Primary results were published by Miller et al. in JAMA (2016; PMID 27533157; DOI 10.1001/jama.2016.11136). Abaloparatide reduced the relative risk of new morphometric vertebral fractures by 86% versus placebo, and the Kaplan-Meier estimated nonvertebral fracture rate was 2.7% (abaloparatide) versus 4.7% (placebo), a 43% relative risk reduction. Bone mineral density (BMD) increased significantly at the lumbar spine, total hip, and femoral neck compared with placebo (all P < 0.001). Hypercalcemia occurred in 3.4% of the abaloparatide group versus 6.4% in the teriparatide group (P = 0.006), indicating a more favorable calcium-related safety profile.

A high-fracture-risk sub-analysis of ACTIVE (n = 1,400; those meeting elevated FRAX criteria) reported a 91% relative risk reduction in vertebral fractures and 54% in nonvertebral fractures versus placebo, and abaloparatide's reduction in major osteoporotic fractures (78%) significantly exceeded that of teriparatide (23%; P = 0.007) in this subgroup.

The Phase 3 ACTIVExtend study followed ACTIVE participants with 24 months of open-label alendronate (abaloparatide-then-alendronate, n = 558; placebo-then-alendronate, n = 581). Over the combined 43-month period, the sequential abaloparatide group achieved an 84% relative risk reduction in vertebral fractures, 39% in nonvertebral fractures, 50% in major osteoporotic fractures, and 34% in clinical fractures versus the placebo-then-alendronate group. No hip fractures occurred in the abaloparatide-then-alendronate arm versus five in the comparator arm.

The ATOM trial (NCT03512262; PMID 36190391; DOI 10.1002/jbmr.4719; JBMR 2022) examined 228 men with osteoporosis (abaloparatide n = 149, placebo n = 79) for 12 months. Lumbar spine BMD increased by 8.48% with abaloparatide versus 1.17% with placebo; total hip increased 2.14% versus 0.01%; femoral neck increased 2.98% versus 0.15% (all P < 0.0001). This evidence supported FDA approval for men in December 2022.

Typical dosage: 80 mcg (daily).

The FDA-approved dosage for Tymlos (abaloparatide) in the United States is 80 mcg administered subcutaneously once daily into the periumbilical abdominal region. The drug is supplied as a pre-filled, single-patient-use disposable pen containing 3,120 mcg in 1.56 mL (2,000 mcg/mL), delivering 30 doses of 80 mcg in 40 microliters each.

• Maximum lifetime treatment duration: 2 years. Cumulative lifetime exposure beyond 2 years is not recommended given the osteosarcoma signal in rat studies and the absence of long-term human safety data beyond this window. • Calcium and vitamin D supplementation should be provided if dietary intake is insufficient, consistent with standard osteoporosis management. • Before first use, the pen must be stored under refrigeration at 2°C to 8°C (36°F to 46°F). After first use, it may be stored at room temperature (20°C to 25°C; 68°F to 77°F) for up to 30 days. • In clinical practice, injection is typically administered at any consistent time of day; patients are advised to sit or lie down for the first several minutes after injection to minimize orthostatic hypotension, particularly during the first few doses. • A transdermal patch formulation (abaloparatide-solid microstructured transdermal system; sMTS) at doses of 50, 100, and 150 mcg was evaluated in Phase 2 studies and demonstrated BMD gains (approximately 2.0% total hip at 100 mcg over 18 months), though fracture-endpoint data for this route are not available as of the writing of this entry. • Sequential antiresorptive therapy (e.g., alendronate) following completion of abaloparatide is standard practice to consolidate BMD gains, as demonstrated in ACTIVExtend.

This information is provided for educational purposes only and does not constitute medical advice. Dosing decisions must be individualized by a qualified healthcare provider.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most rigorously studied combination strategy for abaloparatide is sequential use followed by an antiresorptive agent. In ACTIVExtend, transition to oral alendronate after 18 months of abaloparatide preserved and extended fracture risk reductions over an additional 24 months — a strategy supported by Phase 3 randomized trial data. The mechanistic rationale is that anabolic therapy builds new bone architecture, and subsequent antiresorptive therapy prevents the resorptive rebound that can erode accrued BMD gains after anabolic agent cessation.

Sequential use followed by denosumab (a RANK-L inhibitor) is a plausible clinical strategy, supported by data from analogous teriparatide-to-denosumab sequences showing large cumulative BMD gains; however, abaloparatide-specific randomized trial data for this sequence are limited and this approach is based in part on extrapolation and expert opinion.

Concurrent combination of abaloparatide with bisphosphonates during the anabolic phase is generally not recommended, as bisphosphonates suppress the bone remodeling turnover that anabolic agents depend on, potentially attenuating the osteoblast response. This attenuation has been documented with teriparatide co-administered with alendronate, and the same pharmacological reasoning applies to abaloparatide.

Abaloparatide is routinely co-administered with calcium (typically 1,000-1,200 mg/day total dietary plus supplemental) and vitamin D (typically 400-1,000 IU/day), as in all osteoporosis regimens; this is standard supportive care rather than a pharmacodynamic combination. Anecdotal reports of stacking abaloparatide with vitamin K2 or magnesium for bone health exist in patient communities, but these have no controlled clinical evidence to support them.

Abaloparatide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Similar to teriparatide but milder

Abaloparatide carries a black box warning regarding osteosarcoma. In rat studies, abaloparatide caused a dose-dependent increase in osteosarcoma incidence. No causal relationship between abaloparatide and osteosarcoma in humans has been established, but the drug is contraindicated in patients with conditions predisposing to osteosarcoma (e.g., Paget disease of bone, unexplained elevation of alkaline phosphatase, prior external beam or implant radiation to the skeleton, hereditary bone disorders). Maximum lifetime use is capped at 2 years.

Adverse effects reported in the ACTIVE trial at a frequency of 5% or greater in the abaloparatide 80 mcg group include: hypercalcemia (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), and hypercalciuria. Orthostatic hypotension can occur within 4 hours of injection, typically presenting with early doses; patients are advised to inject while seated or lying down. Injection site reactions (erythema, pain) are common, particularly the erythematous response noted prominently in the ATOM trial (men).

Compared with teriparatide, abaloparatide's transient PTH1R signaling produces significantly lower rates of hypercalcemia (3.4% vs 6.4% in ACTIVE; P = 0.006), an attribute attributed to reduced sustained cAMP-mediated calcium mobilization.

Contraindications include: known hypersensitivity to abaloparatide or excipients, open epiphyses (pediatric patients), Paget disease or other metabolic bone disease other than osteoporosis, elevated alkaline phosphatase of unknown etiology, and prior skeletal radiation therapy. Abaloparatide is not recommended in patients with pre-existing hypercalcemia or hypercalcemic disorders such as primary hyperparathyroidism. No clinically significant drug interactions involving cytochrome P450 enzymes have been identified at therapeutic concentrations.